key: cord-0691636-am3t66gj authors: Sekimoto, Masao; Imai, Toru; Hidaka, Shinji; Chiba, Nobutaka; Sakurai, Atsushi; Hata, Mitsumasa; Kikuchi, Norikazu title: Elevated INR in a COVID‐19 patient after concomitant administration of favipiravir and warfarin: A case report date: 2021-08-02 journal: J Clin Pharm Ther DOI: 10.1111/jcpt.13499 sha: 3fe041694ec26dde4d9b6d6a9c19e382ea24020f doc_id: 691636 cord_uid: am3t66gj WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID‐19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported. CASE SUMMARY: Our patient was taking warfarin for deep vein thrombosis. The international normalized ratio (INR) was stable (1.65 to 2.0); however, it increased to 4.63 after administering favipiravir. The patient had no other factors justifying this change. WHAT IS NEW AND CONCLUSION: Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID‐19 patients. Favipiravir shows potent in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 1 and is reported to be effective for coronavirus disease 2019 (COVID-19). 2, 3 Favipiravir is metabolized mainly by aldehyde oxidase and partly by xanthine oxidase, 4 but not by cytochrome P-450 (CYP); therefore, drug-drug interactions (DDIs) are less likely. However, pharmaceutical company data indicate that favipiravir has a potent inhibitory effect on CYP2C8 and may cause DDIs that are not yet reported. 5 Warfarin, an anticoagulant used in the prevention and treatment of various thrombotic disorders, acts by inhibiting the synthesis of vitamin K-dependent clotting factors. 6 Warfarin has a narrow therapeutic index; a small change in its plasma levels may result in concentration-dependent adverse drug reactions/ therapeutic failure. Therefore, its dose must be tailored for each patient according to the individual response, measured as the INR, and the condition being treated. Warfarin contains a racemic (1:1) mixture of a pair of optical isomers (S-warfarin and R-warfarin). S-warfarin is metabolized by CYP2C9, and R-warfarin is metabolized by CYP1A2 and CYP3A4. 7 Furthermore, involvement of CYP2C8 in the metabolism of S-warfarin and R-warfarin has been reported. 8 It can be inferred that favipiravir, a CYP2C8 inhibitor, may enhance the effects of warfarin. However, no reports are indicating that favipiravir interacts with warfarin and increases the INR. Here, we report a case of elevated INR in a COVID-19 when favipiravir and warfarin were concomitantly administered. The patient was a 76-year-old man initially hospitalized for an intramuscular hematoma treatment in the left thigh. The patient's medical history included abdominal aortic aneurysm, chronic subdural hematoma, acute aortic dissection, deep vein thrombosis and neurogenic bladder. The medication history included warfarin, distigmine, urapidil, ferrous sodium citrate, magnesium oxide and pregabalin. During hospitalization, the patient underwent a reverse transcriptase polymerase chain reaction assay and tested positive for COVID-19 (day 1), after coming in close contact with an infected patient. Baseline characteristics before favipiravir initiation are shown in Table 1 . Laboratory findings revealed increased serum creatinine, CRP, and D-dimer levels, decreased WBC and platelet counts. He was taking warfarin (2.0 mg/day) for deep vein thrombosis, and his INR was in the range of 1.6-2.0, within the target therapeutic range (1.6-2.6). On day 2, the patient had a fever of 40.8℃, a low blood pressure (73/56 mmHg), a high heart rate (105 beats per minute), a respiratory rate of 22 breaths per minute and a low oxygen saturation (92% with nasal O 2 at 2 L/min). Because the patient's condition suddenly deteriorated, favipiravir was administered (orally at 1800 mg twice daily for the first dose and 800 mg twice daily for 14 days; Figure 1 ). Furthermore, the following drugs were administered: ciclesonide inhalation (400 μg thrice daily for 14 days), intravenous dexamethasone (6.6 mg once daily for 10 days), intravenous ceftriaxone (1 g once daily), carbocisteine (500 mg thrice daily) and vonoprazan (10 mg once daily). When favipiravir was initiated on day 2, INR was 1.43, slightly below the therapeutic range. However, on day 5, the INR increased to 3.84; therefore, warfarin was discontinued. Moreover, ceftriaxone was also discontinued because of suspected DDIs, whereas other drugs were continued. Blood data showed no hepatic dysfunction, and there was no change in dietary content or volume. On day 6, the INR further increased to 4.63 despite the discontinuation of warfarin. Vitamin K2 was administered intravenously at 40 mg/day to antagonize the excess anticoagulant action. On day 9, warfarin was restarted at 1.0 mg/day when the INR was 1.52. Warfarin was increased to 2.0 mg/day from day 11. On day 12, dexamethasone and vonoprazan were terminated, and favipiravir and ciclesonide were continued. However, on day 15, the INR increased to 2.73, and warfarin was reduced to 1.5 mg/day, but INR increased to 3.74 by day 17 and was discontinued. Subsequently, vitamin K2 was readministered at 20 mg/day on day 18, and the patient was switched to another anticoagulant. COVID-19 can become serious in high-risk individuals, such as the elderly and those with multiple comorbidities. 9 Multiple drug use is inevitable in COVID-19 treatment, especially for patients with comorbidities (hypertension, diabetes and cardiovascular diseases) and COVID-19 complications (such as acute respiratory distress syndrome, shock, arrhythmia and acute kidney injury). Although DDIs must be closely monitored in clinical practice, the information about DDIs caused by new drugs, including favipiravir, is currently limited. This is the first report of elevated INR in a COVID-19 patient when warfarin and favipiravir were administered concomitantly. In this case, the patient's medication adherence was good, and he was taking his medication properly before admission. After admission, he took the same dose of warfarin, and his INR was stable at 1.65-2.0. Therefore, the increase in INR was not due to the patient's hypersensitivity or improving adherence with hospitalization but might have been due to DDIs. INR increased from the second day of starting favipiravir. Factors that affect the INR include diet, liver dysfunction and the concomitant use of drugs. 10 The patient adhered to a warfarin-only diet with limited vitamin K content throughout the hospitalization and had a normal liver function. The regular medications, distigmine, urapidil, ferrous sodium citrate, magnesium oxide and pregabalin, continued. Additionally, COVID-19 alone does not change the INR. 11 From day 2, the patient was treated with multiple drugs, including favipiravir, ceftriaxone, dexamethasone, ciclesonide and vonoprazan. Ceftriaxone, which has been reported to interact with warfarin, 12 was discontinued; however, the INR continued to increase. INR elevation has also been reported when highdose dexamethasone (>40 mg/day) and warfarin are concomitantly administered. 13 The underlying mechanism for DDIs involves the action of high-dose synthetic glucocorticoids on Niemann-Pick C1like 1 protein. 14 However, the dose of dexamethasone in this patient was 6.6 mg, which was too low to cause any DDIs. Ciclesonide, an inhaled drug, has a low transferability (<1%) of active metabolites into the blood; therefore, it carries little to no risk of causing DDIs. Although CYP2C19 is inhibited by vonoprazan, 15 20 Using DIPS results, the interaction between favipiravir and warfarin was rated as 'probable', which supported an interaction possibility. Here, favipiravir increased the INR in a patient taking warfarin, and the underlying mechanism may involve its inhibitory effect on CYP2C8. However, the exact mechanism is unknown, as no preliminary studies on the interaction between favipiravir and warfarin have been conducted to date. Therefore, we believe that further research is needed to investigate the interaction possibility between favipiravir and warfarin. We present a case in which DDIs between favipiravir and warfarin lead to elevated INR. In COVID-19 patients, the INR should be carefully monitored when these drugs are used concomitantly. No conflicts of interest have been declared. This case report was reviewed and approved by the institutional review board of Nihon University Hospital. Written informed consent was obtained from the patient for publication of this case report and any accompanying data. The data that support the findings of this study are available from the corresponding author upon reasonable request. Masao Sekimoto https://orcid.org/0000-0001-9895-6059 Shinji Hidaka https://orcid.org/0000-0001-5605-4209 Favipiravir: A new and emerging antiviral option in COVID-19 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mildto-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection The Drug Interview Form of Favipiravir (Avigan®) Pharmacogenetics of oral anticoagulants Human P450 metabolism of warfarin Association of warfarin dose with genes involved in its action and metabolism COVID-19 diagnosis and management: a comprehensive review High INR on warfarin Analysis of coagulation parameters in patients with COVID-19 in Shanghai Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis Clinical importance of drug-drug interaction between warfarin and prednisolone and its potential mechanism in relation to the Niemann-Pick C1-like 1-mediated pathway Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of Proguanil, a CYP2C19 substrate, in healthy volunteers Expression of hepatic drugmetabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast Proposal for a new tool to evaluate drug interaction cases